[1] |
XIANG Yunxia, PU Wen, LI Dongfeng, WANG Jie.
Effects of pharmacists' intervention on anticoagulant management of patients treated with warfarin after heart valve replacement
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 545-549.
|
[2] |
CHEN Li-xiu.
Clinical Efficacy and Safety of Low Molecular Weight Heparin Combined with Warfarin in Anticoagulant Treatment of Acute Submassive Pulmonary Embolism
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(11): 651-654.
|
[3] |
ZHANG Ya-tong, FU Chun-yi, LI Zheng, DONG Fan, HU Xin.
Anticoagulation Effect and Association Analysis in Patients on Routine Warfarin Dosage
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 567-569.
|
[4] |
.
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 570-570.
|
[5] |
.
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 571-572.
|
[6] |
ZHOU Hui-ping,LI Zhi-quan,CHEN Xiao-yan,CHEN Yong-chun.
Effect of Rivaroxaban and Low Molecular Heparin to Prevent Deep Venous Thrombosis in the Abdomen after Radical Resection of Tumor
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(2): 73-75.
|
[7] |
YANG Yu-hui, ZHENG Wei-xing, HUANG Ming-fang, CAO Xiao-zhi, ZHANG Wen-li LIU Dong-lin, LUO Zhu-rong.
Safety and Short-term Efficacy of Ticagrelor in Patients with Acute Coronary Syndromes in Chinese
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(7): 390-393.
|
[8] |
WEN Li, HAN Xing, ZHOU Hao, ZHANG Xin-chao.
The Management of Hemorrhage Lead by New Oral Anticoagulants Dabigatran and Rivaroxaban
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(1): 15-18.
|
[9] |
ZHAO Ying-qi ,GAO Na ,YIN Kai .
Application Status and Development Direction of Anticoagulant in Continuous Renal Replacement Therapy
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(11): 658-662.
|
[10] |
ZHAO Yu –dong, LI Xiao -feng .
Analysis of 28 Adverse Drug Reaction Cases of Protamine after Cardiopulmonary Bypass in Children
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(8): 488-491.
|
[11] |
.
[J]. Chinese Journal of Pharmacovigilance, 2011, 8(8): 512-512.
|